Patti, A.M.; Giglio, R.V.; Papanas, N.; Serban, D.; Stoian, A.P.; Pafili, K.; Al Rasadi, K.; Rajagopalan, K.; Rizvi, A.A.; Ciaccio, M.;
et al. Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes. Medicina 2022, 58, 109.
https://doi.org/10.3390/medicina58010109
AMA Style
Patti AM, Giglio RV, Papanas N, Serban D, Stoian AP, Pafili K, Al Rasadi K, Rajagopalan K, Rizvi AA, Ciaccio M,
et al. Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes. Medicina. 2022; 58(1):109.
https://doi.org/10.3390/medicina58010109
Chicago/Turabian Style
Patti, Angelo Maria, Rosaria Vincenza Giglio, Nikolaos Papanas, Dragos Serban, Anca Pantea Stoian, Kalliopi Pafili, Khalid Al Rasadi, Kanya Rajagopalan, Ali A. Rizvi, Marcello Ciaccio,
and et al. 2022. "Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes" Medicina 58, no. 1: 109.
https://doi.org/10.3390/medicina58010109
APA Style
Patti, A. M., Giglio, R. V., Papanas, N., Serban, D., Stoian, A. P., Pafili, K., Al Rasadi, K., Rajagopalan, K., Rizvi, A. A., Ciaccio, M., & Rizzo, M.
(2022). Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes. Medicina, 58(1), 109.
https://doi.org/10.3390/medicina58010109
